Sage Rhino Capital’s AstraZeneca AZN Stock Holding History

Sage Rhino Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.01M	Sell	5,336 -80	-1%	-$15K	0.16%	104
2026 Q1	$1.07M	Buy	5,416 +79	+1%	+$15.2K	0.2%	91
2025 Q4	$981K	Sell	5,337 -1,010	-16%	-$177K	0.19%	98
2025 Q3	$974K	Buy	6,347 +221	+4%	+$33.4K	0.19%	98
2025 Q2	$856K	Sell	6,126 -4	-0.1%	-$561	0.18%	97
2025 Q1	$901K	Buy	6,130 +198	+3%	+$28.6K	0.21%	91
2024 Q4	$777K	Sell	5,932 -80	-1%	-$11.2K	0.17%	102
2024 Q3	$937K	Buy	6,012 +74	+1%	+$11.9K	0.21%	94
2024 Q2	$926K	Buy	5,938 +124	+2%	+$18.7K	0.22%	90
2024 Q1	$788K	Buy	5,814 +123	+2%	+$16.3K	0.19%	102
2023 Q4	$767K	Sell	5,691 -67	-1%	-$8.71K	0.2%	98
2023 Q3	$780K	Buy	5,758 +77	+1%	+$10.5K	0.22%	89
2023 Q2	$813K	Buy	5,681 +294	+5%	+$43.3K	0.23%	91
2023 Q1	$748K	Buy	5,387 +75	+1%	+$10.1K	0.22%	89
2022 Q4	$720K	Sell	5,312 -183	-3%	-$22.9K	0.23%	89
2022 Q3	$603K	Sell	5,495 -166	-3%	-$21.1K	0.24%	77
2022 Q2	$748K	Buy	5,661 +207	+4%	+$27.2K	0.29%	59
2022 Q1	$724K	Buy	5,454 +252	+5%	+$30.2K	0.22%	83
2021 Q4	$606K	Buy	5,202 +663	+15%	+$78K	0.17%	107
2021 Q3	$545K	Buy	4,539 +428	+10%	+$49.8K	0.17%	99
2021 Q2	$492K	Buy	4,111 +218	+6%	+$23.9K	0.15%	109
2021 Q1	$387K	Buy	3,893 +74	+2%	+$7.44K	0.13%	116
2020 Q4	$382K	Sell	3,819 -1,202	-24%	-$127K	0.15%	109
2020 Q3	$550K	Buy	5,021 +95	+2%	+$10.6K	0.27%	76
2020 Q2	$521K	Buy	4,926 +104	+2%	+$10.7K	0.28%	79
2020 Q1	$431K	Buy	4,822 +2,104	+77%	+$198K	0.31%	71
2019 Q4	$271K	Buy	2,718 +51	+2%	+$4.8K	0.15%	116
2019 Q3	$238K	Buy	2,667 +66	+3%	+$5.72K	0.15%	119
2019 Q2	$215K	Buy	+2,601	New	+$204K	0.14%	121

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Sage Rhino Capital's AZN Position: Q2 2026 in Review

Sage Rhino Capital reduced its AstraZeneca (AZN) stake by 1.5% in Q2 2026, selling an estimated $15K and leaving 5,336 shares worth $1.01M. The position accounts for 0.16% of the portfolio, ranked #104.

Sage Rhino Capital first reported a position in AZN in Q2 2019 and has held it in 29 quarters since. The position peaked at $1.07M in Q1 2026. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Sage Rhino Capital held 5,336 shares of AstraZeneca worth $1.01M as of Q2 2026.
Sage Rhino Capital sold 80 AstraZeneca shares in Q2 2026, an estimated $15K.
AstraZeneca made up 0.16% of Sage Rhino Capital's portfolio in Q2 2026, its #104 holding.
Sage Rhino Capital first reported a position in AstraZeneca in Q2 2019 and has held it in 29 quarters since.
Sage Rhino Capital's AstraZeneca position peaked at $1.07M in Q1 2026.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Sage Rhino Capital's 13F filing for Q2 2026, filed 3 Aug 2026.